American Century Companies Inc. Purchases 21,710 Shares of DaVita Inc. $DVA

Key Points

• American Century Companies Inc. increased its stake in DaVita Inc. by 34.6% during the 1st quarter, owning approximately 84,513 shares valued at around $12.9 million.
• Several analysts have recently revised their ratings on DaVita, with Barclays lowering the price target from $169 to $160, while Wall Street Zen upgraded the stock from "hold" to "buy."
• DaVita reported a 6.1% year-over-year increase in revenue, generating $3.38 billion in the latest quarter and exceeding earnings expectations with an EPS of $2.95.

American Century Companies Inc. grew its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 34.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 84,513 shares of the company's stock after purchasing an additional 21,710 shares during the quarter. American Century Companies Inc. owned about 0.11% of DaVita worth $12,928,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Brandywine Global Investment Management LLC grew its stake in shares of DaVita by 19.3% during the first quarter. Brandywine Global Investment Management LLC now owns 129,219 shares of the company's stock worth $19,767,000 after purchasing an additional 20,947 shares during the period. Sei Investments Co. raised its stake in shares of DaVita by 4.0% in the 1st quarter. Sei Investments Co. now owns 94,411 shares of the company's stock valued at $14,428,000 after purchasing an additional 3,642 shares during the period. Neuberger Berman Group LLC grew its holdings in shares of DaVita by 684.0% in the 1st quarter. Neuberger Berman Group LLC now owns 65,364 shares of the company's stock valued at $9,999,000 after acquiring an additional 57,027 shares in the last quarter. Boston Partners grew its holdings in shares of DaVita by 2.0% in the 1st quarter. Boston Partners now owns 91,225 shares of the company's stock valued at $13,947,000 after acquiring an additional 1,772 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of DaVita in the 1st quarter valued at about $112,000. Institutional investors own 90.12% of the company's stock.

Insider Activity at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by corporate insiders.

DaVita Stock Performance

Shares of DVA stock traded down $1.55 on Thursday, hitting $136.01. 990,239 shares of the stock were exchanged, compared to its average volume of 887,612. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $9.72 billion, a PE ratio of 13.37, a P/E/G ratio of 0.99 and a beta of 1.09. DaVita Inc. has a one year low of $126.07 and a one year high of $179.60. The firm's 50 day moving average is $139.71 and its two-hundred day moving average is $143.12.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period in the prior year, the company earned $2.00 EPS. The company's quarterly revenue was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Barclays lowered their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, August 22nd. Finally, Truist Financial set a $148.00 price objective on shares of DaVita in a research report on Friday, August 8th. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $164.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.